Logo 11 Jun 2022

Deep dive | Secret agents: The regulatory turf battle that will determine the future of US-listed Chinese companies

Subscribe to keep reading.

Sign up to stay briefed on what the Chinese government is doing, thinking, and saying.

Try it free

Already a subscriber? Log in.

For the past several months, a range of investors, officials, and corporate executives have been on the edges of their seats when it comes to one important China issue: whether or not US and Chinese regulators can strike a deal on cross-border audits to avoid the mass delisting of US-listed Chinese ...



More recent developments

Logo October 29, 2025
Quick take | Is China angling to become the world’s lab partner?

Premier Li Qiang wants East Asian countries to participate in more research collaborations. That was the spirit of the speech he delivered on October 27 at the 28th ASEAN Plus China, Japan, and South Korea Summit. What caught our eye:… Read More »

Logo September 11, 2025
Quick take | Washington’s fear of Chinese biotech could be just what Beijing needs

The Trump administration is considering an executive order (E.O.) that would block US pharma companies from buying Chinese-developed drug candidates.  Per the New York Times: “At the heart of the possible clampdown is a drafted executive order that threatens to… Read More »

Logo August 28, 2025
Deep dive | The AI Plus plan – China’s blueprint for AI diffusion

On August 26, the State Council published a high-level directive on implementing the AI Plus policy initiative.  This document is a big deal: It represents China's most detailed plan to date addressing how the country intends to develop and diffuse… Read More »